Peptide reference
First isolated from rabbit cerebral venous blood during induced slow-wave sleep in the 1970s. Small human trials in the 1980s–90s showed reduced stress markers and some sleep architecture effects. The problem: the mechanism isn't clear, the blood-brain barrier penetration is disputed, and endogenous DSIP levels are difficult to measure. Decades of research have produced more questions than answers.
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first isolated from cerebral venous blood of rabbits during induced slow-wave sleep and shown to increase NREM sleep in recipient animals.
DSIP, listed as Emideltide in FDA documents, is a nine-amino-acid neuropeptide first isolated from the blood of sleeping rabbits in 1977. It's proposed to promote deep, slow-wave sleep by acting on the central nervous system, though no specific receptor has been identified and the pathway isn't well characterized.
The best-controlled human trial, a double-blind study in chronic insomnia patients, found DSIP gave no major therapeutic benefit over placebo. Earlier reports of sleep promotion came from smaller, less rigorous studies. The honest read is that the sleep idea is genuinely interesting, but the strongest human evidence available doesn't support it working.
No. DSIP, under its FDA name Emideltide, has no FDA-approved drug application. On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) recommended against inclusion of Emideltide (DSIP) on the 503A Bulk Drug Substances List, the list that covers pharmacy compounding. The uses put to the committee were opioid withdrawal, chronic insomnia and narcolepsy. That's advice to the FDA, and FDA final action is pending.
The evidence for that is one open, uncontrolled clinical trial from 1998 with no placebo group. It's the main human evidence behind that use, and it's thin. A single uncontrolled report from nearly three decades ago isn't the same as an established treatment.
Wolverine Health is building physician-supervised peptide protocols. Get early access.
Join the waitlist